It has been extensively documented that overexpression of GRP78 contributes to resistance in various cancers, such as sorafenib resistance in liver cancer [108], sunitinib resistance in renal cancer [109], and gefitinib resistance in NSCLC [110]. Here, HSPA5 is linked to cancer.